Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.49 |
| ▸ | COMT | P21964 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.45 |
| ▸ | DAO | P14920 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19207691 | 0.81 | POLB (0.50) | RIPK1COMTMEN1KMT2APOLB | |
| SCHEMBL19207575 | 0.70 | RIPK1 (0.48) | RIPK1DAOMEN1KMT2A | |
| Bicarbonate SCHEMBL7575333 | 0.69 | MEN1 (0.60) | DAOMEN1KMT2A | |
| SCHEMBL14719485 | 0.69 | DAO (0.45) | RIPK1COMTDAOMEN1KMT2A | |
| SCHEMBL19207694 | 0.69 | RIPK1 (0.48) | RIPK1DAOMEN1KMT2A | |
| SCHEMBL28264109 | 0.68 | COMT (0.42) | RIPK1COMTDAOMEN1KMT2A | |
| SCHEMBL14114465 | 0.66 | COMT (0.51) | COMTKMT2APRCP | |
| SCHEMBL69492 | 0.66 | MEN1 (0.58) | HCAR2DAOMEN1KMT2APOLB | |
| SCHEMBL19224574 | 0.66 | RIPK1 (0.49) | RIPK1MEN1KMT2A | |
| SCHEMBL8439272 | 0.65 | RXRA (0.58) | DAOMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-118994190-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994191-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114437105-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20240150376-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| CN-114437105-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-109071504-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-03-08 | — | — | CN | disclosed |
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | RIPK1 1507/4885COMT 2755/4885HCAR2 924/4885 |
| US-20200317691-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885COMT 2302/4885HCAR2 3504/4885 |
| US-20240150376-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885COMT 2302/4885HCAR2 3504/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885COMT 2302/4885HCAR2 3504/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885COMT 2302/4885HCAR2 3504/4885 |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885COMT 2302/4885HCAR2 3504/4885 |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885COMT 2302/4885HCAR2 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.